This is the authors' abstract. We don't add key points for this paper.
ABSTRACT β-thalassemia pathology is not only due to loss of β-globin ( HBB ), but also erythrotoxic accumulation and aggregation of the β-globin binding partner, α-globin ( HBA1/2 ). Here we describe a Cas9/AAV6-mediated genome editing strategy that can replace the entire HBA1 gene with a full-length HBB transgene in β-thalassemia-derived hematopoietic stem and progenitor cells (HSPCs), which is sufficient to normalize β-globin:α-globin mRNA and protein ratios and restore functional adult hemoglobin tetramers in patient-derived red blood cells. Edited HSPCs were capable of long-term and bi-lineage hematopoietic reconstitution in mice, establishing proof-of-concept for replacement of HBA1 with HBB as a novel therapeutic strategy for curing β-thalassemia.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Cromer et al. (2020) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: